DexTech Medical AB (XSAT:DEX) PS Ratio: (As of Jul. 08, 2026)


XSAT:DEX DexTech Medical AB XSAT:DEX
17 GF Score
Price kr9.70
! 2 Warning Signs
View Full Analysis

What is DexTech Medical AB PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, DexTech Medical AB's share price is kr9.70. DexTech Medical AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00. Hence, DexTech Medical AB's PS Ratio for today is .

The historical rank and industry rank for DexTech Medical AB's PS Ratio or its related term are showing as below:

During the past 13 years, DexTech Medical AB's highest PS Ratio was 8786.43. The lowest was 226.92. And the median was 1033.00.

XSAT:DEX's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.59
* Ranked among companies with meaningful PS Ratio only.

DexTech Medical AB's Revenue per Sharefor the three months ended in Mar. 2026 was kr0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00.

Back to Basics: PS Ratio


DexTech Medical AB  (XSAT:DEX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


DexTech Medical AB PS Ratio Related Terms


DexTech Medical AB PS Ratio Historical Data

* Premium members only.

The historical data trend for DexTech Medical AB's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexTech Medical AB PS Ratio Chart

DexTech Medical AB Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DexTech Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XSAT:DEX vs VRTX, REGN, ALNY: PS Ratio Comparison

For the Biotechnology subindustry, DexTech Medical AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexTech Medical AB PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DexTech Medical AB's PS Ratio distribution charts can be found below:

* The bar in red indicates where DexTech Medical AB's PS Ratio falls into.


XSAT:DEX
17GF Score
DexTech Medical AB XSAT:DEX
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexTech Medical AB PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

DexTech Medical AB's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=9.70/0
=

DexTech Medical AB's Share Price of today is kr9.70.
DexTech Medical AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


DexTech Medical AB Business Description

Address Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
17GF Score

Get the complete analysis for XSAT:DEX

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr9.70
Price